• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1253885 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type. b- E& X  a  W+ l! ?9 q; a
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 0 h! H9 i3 i' N+ r) P
+ Author Affiliations
3 n: H, j- S1 S7 l- e7 W: |7 D. E5 D9 r+ ?4 N
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan : a6 a0 M* q# Z# N, w0 }' d
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 1 J$ a, P3 x8 a, F7 M$ o
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
: V; b! I8 Z  P8 Z! j- m5 L& e0 I4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
1 a# A4 l' m& k3 O& z5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan & b. Y' P( q1 W0 T  j: z8 B
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
8 S) }; y  S1 j2 j: F. r7Kinki University School of Medicine, Osaka 589-8511, Japan % |5 h( \  _1 C6 }, y+ [# @) x2 _4 w
8Izumi Municipal Hospital, Osaka 594-0071, Japan 4 A' D  ?8 g1 j3 q
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan / B# F& Z  y. x+ k; m$ R
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp   n# j. w- ]: E* B! x$ `7 z$ e* `
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 5 E7 G5 Q  a, h  g, K# z% i* p& M. w: \

( m0 H* P- d. _6 q( P, U  P2 z( i
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type " \9 a6 k% @# D# b; }) A

" F9 s% u2 @  c: [3 O$ t2 d& JAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
. e9 N7 G  q0 e) A0 J% O6 M/ F  y% C, b
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
  x7 Q( \- ?4 |; g! l- Y6 P( V6 J1 M, U; a& E
Published online on: Thursday, December 1, 2011
( F4 N8 {# Z+ m; n# a! K4 g
* y) V8 t) C: `Doi: 10.3892/ol.2011.507 2 }- j1 `, K7 m

( f2 `! E) B- `* N( C2 w7 ?: I2 EPages: 405-410
6 x0 p& }) `: @( s. {4 r5 I" Y" A+ ~; \- m
Abstract:0 H1 Z- C  `4 |7 L; H* \
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
/ G% H: j# w$ k& q3 w" _ % T! [7 T; V5 O! w/ P' h
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population0 e* T  {9 s/ H; c
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 / m) F- M: p7 v
+ Author Affiliations2 a  S1 c4 f, {% @% R5 q9 q  u! v: q
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
: J) _/ X0 @6 Y  F, Q" v& }2Department of Thoracic Surgery, Kyoto University, Kyoto
. s9 `1 V5 E6 B' z) F; K7 ?3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan 8 @- a4 y0 F' g
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
( A+ i, V; |8 p2 t* n# a. W6 t# iReceived September 3, 2010.
$ d/ ~% K6 [0 l4 pRevision received November 11, 2010.
4 k( y* v* t5 DAccepted November 17, 2010.
+ X& G5 d: G' E8 S/ p! A! b  BAbstract8 W7 G2 @0 |4 R" s- t4 P2 `, Y
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. - Y- z& ]3 T0 N3 o. W( T  F8 G
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
5 M& {9 t/ j$ \2 [& DResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. ' G6 h+ d, q' B3 M$ w
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
% b5 L" `. d* q! P, Z9 ~+ ~; I
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。) ^! A7 C* p8 r( P
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
! @; l6 L# N+ t) t4 k; Q* {& a: i
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
2 A5 s( s- H) G& H- w+ rhttp://clinicaltrials.gov/ct2/show/NCT01523587
7 f% a& a- Z' j: M% y
: ^, ~( d' e0 K8 `( O  w& GBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC! \% \9 t4 P9 Z7 [) u
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 % \0 M% J7 n; e( p& O2 j6 M
# `' c& \* t- Z! G  L
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
2 b! d, W8 V2 O2 x至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

/ e! M* K1 _9 S+ M3 C' G9 [  W没有副作用是第一追求,效果显著是第二追求。1 ?; T/ _$ I; }
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表